GTX INC Uncategorized Contracts & Agreements
35 Contracts & Agreements
- Description of Securities of the Registrant (Filed With SEC on March 7, 2024)
- Amendment No. 2 to the Inducement Plan dated December 15, 2021 (Filed With SEC on March 10, 2022)
- Description of Securities of the Registrant (Filed With SEC on March 10, 2022)
- Open Market Sale Agreement (Filed With SEC on December 17, 2021)
- First Amendment to Contingent Value Rights Agreement dated November 1, 2021 by and between the Registrant, Marc S. Hanover, as the Holders Representative, and Computershare Inc.,... (Filed With SEC on November 4, 2021)
- Open Market Sale Agreement (Filed With SEC on May 28, 2021)
- Engagement Letter between the Registrant and H.C. Wainwright & Co., LLC, dated as of December 9, 2020 (Filed With SEC on March 11, 2021)
- Engagement Letter between Oncternal Therapeutics, Inc. and H.C. Wainwright & Co., LLC, dated as of May 15, 2020 (Filed With SEC on May 21, 2020)
- Description of Securities of Oncternal Therapeutics, Inc (Filed With SEC on March 16, 2020)
- Research agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, on behalf of its San Diego Campus, dated November 3, 2016 (Filed With SEC on April 8, 2019)
- Form of Lock-Up Agreement, dated March 6, 2019, by each of the parties named in each agreement therein (Filed With SEC on March 7, 2019)
- GTx, INC. 175 TOYOTA PLAZA, 7THFLOOR MEMPHIS, TN 38103 (Filed With SEC on November 12, 2013)
- GTx, INC. 175 TOYOTA PLAZA, 7THFLOOR MEMPHIS, TN 38103 (Filed With SEC on November 12, 2013)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on August 9, 2011)
- GTx, Inc. (Filed With SEC on June 23, 2011)
- FINANCIAL STATEMENTS (Filed With SEC on May 9, 2011)
- FINANCIAL STATEMENTS (Filed With SEC on May 9, 2011)
- FINANCIAL STATEMENTS (Filed With SEC on May 9, 2011)
- Exhibit No (Filed With SEC on October 27, 2010)
- FINANCIAL STATEMENTS (Filed With SEC on May 4, 2010)
- GTx, Inc. (Filed With SEC on May 6, 2008)
- Exhibit No (Filed With SEC on December 18, 2007)
- FINANCIAL STATEMENTS (Filed With SEC on August 1, 2007)
- FINANCIAL STATEMENTS (Filed With SEC on August 1, 2007)
- FINANCIAL STATEMENTS (Filed With SEC on August 1, 2007)
- EX-10.34 AMENDMENT DATED JUNE 30, 2006 (Filed With SEC on August 9, 2006)
- EX-10.33 AMENDMENT DATED MAY 23, 2006 (Filed With SEC on August 9, 2006)
- Exhibit No (Filed With SEC on October 12, 2005)
- Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract (Filed With SEC on January 15, 2004)
- Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract (Filed With SEC on January 15, 2004)
- Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract (Filed With SEC on January 15, 2004)
- Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract (Filed With SEC on January 15, 2004)
- Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract (Filed With SEC on January 15, 2004)
- Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract (Filed With SEC on December 22, 2003)
- Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract (Filed With SEC on December 22, 2003)
